| Target Price | $198.90 |
| Price | $144.46 |
| Potential | 37.69% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target Insmed Incorporated 2027 . The average Insmed Incorporated target price is $198.90. This is 37.69% higher than the current stock price. The highest price target is $255.15 76.62% , the lowest is $159.58 10.47% . | |
| A rating was issued by 31 analysts: 29 Analysts recommend Insmed Incorporated to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Insmed Incorporated stock has an average upside potential 2027 of 37.69% . Most analysts recommend the Insmed Incorporated stock at Purchase. |
26 Analysts have issued a sales forecast Insmed Incorporated 2026 . The average Insmed Incorporated sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
9 Analysts have issued an Insmed Incorporated EBITDA forecast 2026. The average Insmed Incorporated EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
26 Insmed Incorporated Analysts have issued a net profit forecast 2026. The average Insmed Incorporated net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
26 Analysts have issued a Insmed Incorporated forecast for earnings per share. The average Insmed Incorporated EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
Insmed Incorporated...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Nov 02 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Oct 21 2026 |
| HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Oct 12 2026 |
| Wolfe Research |
Outperform
➜
Peer Perform
|
Downgrade | Oct 12 2026 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Sep 30 2026 |
| Goldman Sachs |
➜
Buy
|
Unchanged | Sep 24 2026 |
| Roth Capital |
Buy
➜
Buy
|
Unchanged | Sep 15 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Nov 02 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Oct 21 2026 |
|
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Oct 12 2026 |
|
Downgrade
Wolfe Research:
Outperform
➜
Peer Perform
|
Oct 12 2026 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Sep 30 2026 |
|
Unchanged
Goldman Sachs:
➜
Buy
|
Sep 24 2026 |
|
Unchanged
Roth Capital:
Buy
➜
Buy
|
Sep 15 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


